Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

DCM Precision Medicine Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03037632
Recruitment Status : Recruiting
First Posted : January 31, 2017
Last Update Posted : March 14, 2019
Sponsor:
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
National Human Genome Research Institute (NHGRI)
Information provided by (Responsible Party):
Ray Hershberger, Ohio State University

Brief Summary:
The aims of the DCM Precision Medicine Study are to test the hypothesis that DCM has substantial genetic basis and to evaluate the effectiveness of a family communication intervention in improving the uptake and impact of family member clinical screening.

Condition or disease Intervention/treatment Phase
Idiopathic Dilated Cardiomyopathy Behavioral: Family Heart Talk Booklet Not Applicable

Detailed Description:
Dilated cardiomyopathy of unknown cause (DCM), known clinically as idiopathic dilated cardiomypathy, is the most common cardiomyopathy and is the leading cause of heart transplantation. DCM affects approximately one million individuals, and so has a major impact on US public health. DCM is commonly asymptomatic until very late in its course when it causes heart failure, disability, and death. Because of its clinical course, any means to identify patients at risk for DCM or to detect DCM in its asymptomatic phase could provide enormous opportunity for intervention to extend lives and prevent late-stage disease. Within this paradigm precision medicine for DCM could greatly impact health care outcomes and costs. Recent advances in DCM genetics have introduced these possibilities, but unresolved questions of familial recurrence risk, genetic etiology, racial differences, and family-based screening must be addressed to move ahead. The central hypothesis of this study, based on published studies of the investigative group, states that DCM has substantial genetic basis. For this study the investigators hypothesize that: (a) 35% of probands of both European and African ancestry (EA/AA) will be classified as familial in a cohort recruited in a multicenter US consortium and given explicit recommendations and assistance to achieve the clinical screening of relatives; (b) approximately 40% of DCM probands, whether categorized as familial or non-familial, or as EA or AA, will have pathogenic or likely pathogenic variants in genes previously implicated in DCM; and (c) a tailored intervention to help DCM probands communicate DCM risk to their family members will improve the uptake and impact of necessary clinical and genetic testing. To test these hypotheses, the investigators propose to: (1) estimate and compare the frequencies of EA and AA DCM probands classified as having familial DCM; (2) estimate and compare the proportions of probands with an identifiable genetic cause of DCM in groups defined by proband classification (familial/non-familial) and ancestry (EA/AA); and (3) evaluate the impact of a randomized intervention to aid and direct family communication on participation of at-risk family members in clinical screening and appropriate follow-up surveillance for DCM. These aims will be accomplished by recruiting a cohort of 1300 DCM probands (600 EA, 600 AA, 100 Hispanic ethnicity), performing cardiovascular clinical screening of 2600 family members, performing genetic testing of probands and affected family members by exome sequencing, returning genetic results, and randomizing probands to an intervention to improve family communication regarding DCM risk. Proving these hypotheses would be transformative for the field: rather than viewing DCM as only a clinical diagnosis, cardiovascular professionals would understand DCM as a genetic disease that should be managed using genetic diagnostic and family-based preventive strategies. These study results would make precision medicine for DCM a reality.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Blinded until intervention is assigned to subject.
Primary Purpose: Prevention
Official Title: Precision Medicine for Dilated Cardiomyopathy in European and African Ancestry
Actual Study Start Date : June 7, 2016
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : June 2021


Arm Intervention/treatment
Experimental: Communication Tool Behavioral: Family Heart Talk Booklet
No Intervention: No Communication Tool



Primary Outcome Measures :
  1. Family clinical screening completed within 12 months from proband enrollment. [ Time Frame: 12 months from proband enrollment. ]
    The probability that a living first-degree relative (FDR) without a previous definitive DCM diagnosis completes clinical screening for DCM within 12 months after proband recruitment

  2. Living first-degree relative adheres to cardiovascular surveillance recommendations after return of genetic results. [ Time Frame: 2.5 years ]
    The probability that a living first-degree relative adheres to surveillance recommendations within 15 months after the proband receives individual genetic test information.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meeting criteria for dilated cardiomyopathy (DCM) :

    • Left ventricular ejection fraction <50%
    • Left ventricular enlargement (A left ventricular end-diastolic dimension > 95%tile population standard based on gender and height).
  • Detectable causes of cardiomyopathy, except genetic, excluded beyond a reasonable doubt at the time of DCM diagnosis (that is, meeting clinical criteria for idiopathic DCM)
  • Any age (including children)
  • Non-Hispanic and Hispanic ethnicity
  • All races (PI pre-approval required for recruitment beyond pre-specified recruitment targets).
  • Ability to give informed consent
  • Ability to communicate in English (except Spanish language at sites approved to recruit individuals of Hispanic ethnicity)
  • Willingness to participate in a family-based study (patient willing to work with a clinical site and/or OSU to facilitate the recruitment and enrollment of family members to the study).

Exclusion Criteria:

  • Coronary artery disease (CAD) causing ischemic cardiomyopathy (> 50% narrowing, any major epicardial coronary artery)
  • Primary valvular disease
  • Adriamycin or other cardiotoxic drug exposure
  • Other forms of cardiomyopathy: Hypertrophic, Restrictive, or Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
  • Congenital heart disease
  • Other detectable causes of dilated cardiomyopathy, including sarcoid and hemochromatosis.
  • Other active multi-system disease that may cause DCM (e.g., active connective tissue disease).
  • Severe and untreated or untreatable hypertension (systolic blood pressures routinely greater than 180 mm Hg and/or diastolic blood pressures greater than 120 mm Hg, and if resistant to multidrug treatment).
  • However, conventional risk factors for DCM, including obesity, routinely treated hypertension, alcohol use, pregnancy or the peri-partum period, or left ventricular noncompaction, will NOT be considered exclusion criteria.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03037632


Contacts
Layout table for location contacts
Contact: Principal Investigator 614-688-1388
Contact: Clinical Research Manager 614-688-9815

  Show 26 Study Locations
Sponsors and Collaborators
Ray Hershberger
National Heart, Lung, and Blood Institute (NHLBI)
National Human Genome Research Institute (NHGRI)
Investigators
Layout table for investigator information
Principal Investigator: Ray Hershberger, MD Ohio State University

Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Ray Hershberger, MD, Ohio State University
ClinicalTrials.gov Identifier: NCT03037632     History of Changes
Other Study ID Numbers: 2015H0309
R01HL128857 ( U.S. NIH Grant/Contract )
First Posted: January 31, 2017    Key Record Dates
Last Update Posted: March 14, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiomyopathies
Cardiomyopathy, Dilated
Heart Diseases
Cardiovascular Diseases
Cardiomegaly